Mario Domenico Rizzato

Mario Domenico Rizzato

Auto-generated profile, based on publicly available information

Mario Domenico Rizzato

Veneto Institute of Oncology IOV‐IRCCS Padua Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
FLFotios Loupakis
Fotios Loupakis
SSShruti Sharma
Shruti Sharma
MDMadiha Derouazi
Madiha Derouazi
SMSabina Murgioni
Sabina Murgioni
PBPaola Biason
Paola Biason
Matteo FassanMatteo Fassan
Matteo Fassan
PURPOSE: More than 50% of patients with stage IV colorectal cancer (metastatic colorectal cancer [mCRC]) relapse postresection. The efficacy of postoperative systemic treatment is limited in this setting. Thus, these patients would greatly benefit from the use of a reliable prognostic biomarker, such as circulating tumor DNA (ctDNA) to identify minimal or molecular residual disease (MRD). PATIENTS AND METHODS: We analyzed a cohort of 112 patients with mCRC who had undergone metastatic resection with curative intent as part of the PREDATOR clinical trial. The study evaluated the prognostic value of ctDNA, correlating MRD status postsurgery with clinical outcomes by using a personalized and tumor-informed ctDNA assay (bespoke multiple PCR, next-generation sequencing assay). Postresection, systemic therapy was given to 39.2% of the patients at the discretion of the treating physician. RESULTS: Postsurgical, MRD positivity was observed in 54.4% (61 of 112) of patients, of which 96.7% (59 of 61) progressed at the time of data cutoff (hazard ratio [HR]: 5.8; 95% CI, 3.5 to 9.7; P < .001). MRD-positive status was also associated with an inferior overall survival: HR: 16.0; 95% CI, 3.9 to 68.0; P < .001. At the time of analyses, 96% (49 of 51) of patients were alive in the MRD-negative arm compared with 52.4% (32 of 61) in the MRD-positive arm. Patients who did not receive systemic therapy and were MRD-negative in the combined ctDNA analysis at two time points had an overall survival of 100%. In the multivariate analysis, ctDNA-based MRD status was the most significant prognostic factor associated with disease-free survival (HR: 5.78; 95% CI, 3.34 to 10.0; P < .001). CONCLUSION: This study confirms that in mCRC undergoing resection of metastases, postoperative MRD analysis is a strong prognostic biomarker. It holds promises for being implemented in clinical decision making, informing clinical trial design, and further translational research.

15 March 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
MRMario Rizzato
Mario Rizzato
SBStefano Brignola
Stefano Brignola
GMGiada Munari
Giada Munari
MGMaura Gatti
Maura Gatti
VDVincenzo Dadduzio
Vincenzo Dadduzio
Matteo FassanMatteo Fassan
Matteo Fassan

28 September 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
MRMargherita Rimini
Margherita Rimini
Eleonora LoiEleonora Loi
Eleonora Loi
CFCarles Fabregat-Franco
Carles Fabregat-Franco
VBValentina Burgio
Valentina Burgio
SLSara Lonardi
Sara Lonardi
ACAndrea Casadei-Gardini
Andrea Casadei-Gardini

29 September 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TTTin-Yun Tang
Tin-Yun Tang
FNFederico Nichetti
Federico Nichetti
BKBenjamin Kaplan
Benjamin Kaplan
SLSara Lonardi
Sara Lonardi
FPFilippo Pietrantonio
Filippo Pietrantonio
MNMonica Niger
Monica Niger
Purpose: BRAF mutations are rare in biliary tract cancers (BTC), but are of interest given the recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a cohort of BRAF-mutant advanced BTC treated with first-line chemotherapy. Furthermore, we investigated the genomic landscape of BRAF class I, II, and III mutations in the intrahepatic cholangiocarcinoma (iCCA) subgroup of BTC.Experimental Design: We analyzed two nonoverlapping cohorts. We examined the genomic landscape of BRAF-mutated iCCA in a “genomic cohort” [187 class I, 82 class II, 113 class III BRAF mutants and 8,026 wildtype (WT)]. We also analyzed median progression-free survival (PFS) and overall survival (OS) on first-line chemotherapy in a separate multi-institutional “clinical cohort” of patients with BTC (including iCCA and extrahepatic cholangiocarcinoma (eCCA) and gallbladder cancer; 41 class I, 32 class II+III BRAF mutants and 1,042 WT).Results: In the entire BTC clinical cohort, the median PFS was shorter for class I [HR, 2.11 (P < 0.001)] and class II+III [HR, 1.72 (P = 0.007)] as compared with BRAF WT. OS was also shorter in class I [HR, 2.04 (P = 0.011)] and class II+III [HR, 1.86 (P = 0.002)] as compared with BRAF WT. In the iCCA subgroup, class I alterations were mutually exclusive with FGFR2, IDH1/2, ERBB2, and KRAS mutations. Class II+III mutations appear to be mutually exclusive with FGFR2 and KRAS.Conclusions: In BTC, all classes of BRAF mutations are associated with a worse prognosis. BRAF mutations occur in 5% of iCCA subgroup and may be mutually exclusive with other targetable mutations.

1 September 2018 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
MSMarta Schirripa
Marta Schirripa
GPGiuseppe Pasqualetti
Giuseppe Pasqualetti
RGRiccardo Giampieri
Riccardo Giampieri
MSMario Scartozzi
Mario Scartozzi
SLSara Lonardi
Sara Lonardi
FLFotios Loupakis
Fotios Loupakis

1 September 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AGAndrea Casadei gardini
Andrea Casadei gardini
Giorgia MarisiGiorgia Marisi
Giorgia Marisi
VDVincenzo Dadduzio
Vincenzo Dadduzio
LGLaura Gramantieri
Laura Gramantieri
LFLuca Faloppi
Luca Faloppi
Mario ScartozziMario Scartozzi
Mario Scartozzi
Purpose: After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenibfor hepatocellular carcinoma (HCC).On the basis of the results of our two retrospective studies, we designed the multicenter INNOVATE study with the aim to validate the role of NOS3 and ANGPT2 polymorphisms in HCC patients treated with sorafenib [NCT02786342]. Experimental Design: This prospective multicenter study was conducted at 10 centres in Italy. All eligible patients received a continuous oral treatment with 400 mg of sorafenib twice daily. Genotyping analysis was performed for NOS3 (rs2070744) and ANGPT2 SNPs (rs55633437). The primary outcome was progression free survival (PFS), while secondary outcomes included overall survival (OS) and disease-control rate (DCR). Results: 165 patients were enrolled between March2016 and June 2018. NOS3 rs2070744 CC/CT genotypes were significantly associated with a higher median PFS(5.9 vs 2.4 months, HR 0.43, p=0.0007) and OS(15.7 vs 8.6 months, HR 0.38, p<0.0001) compared to TT genotype.There was no statistically significant association betweenANGPT2 rs55633437 TT/GT genotypes and PFS(2.4 vs 5.7 months, HR 1.93, p=0.0833) and OS(15.1 vs 13.0 months, HR 2.68, p=0.55) when compared to the other genotype. Following adjustment for clinical covariates,multivariate analysis confirmed NOS3 as an independent prognostic factor for PFS (HR 0.50, p=0.0128)and OS (HR 0.29, p=0.0041). Conclusions: The INNOVATE study met the primary endpoint, confirming that advanced HCC patients with NOS3 rs2070744 CC/CT genotypes had a better prognosis with respect to TT genotype patients.